Search
Phenacemide
go.drugbank.com/drugs/DB01121ApprovedPhenacemide is used to control certain seizures in the treatment of epilepsy. This medicine acts on the central nervous system (CNS) to reduce the number and severity of seizures.
Hyoscyamine
go.drugbank.com/drugs/DB00424ApprovedInvestigational[L31548,L31553] Although hyoscyamine is marketed in the United States, it is not FDA approved.[L31548,L31553] … Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine].[A228423] It is commonly extracted from plants in the _Solanaceae_ or nightshade family.
Mixtures: UR N-C Urinary AntisepticEmbusartan
go.drugbank.com/drugs/DB19949ExperimentalEmbusartan is a small molecule drug. The usage of the INN stem '-sartan' in the name indicates that Embusartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).
Categories: Angiotensin II receptor antagonists, Angiotensin II Type 1 Receptor BlockersStem-cell derived exosome vesicle products
go.drugbank.com/drugs/DB15743ExperimentalExosomes from MSCs carry cytokines and growth factors, like TGFB1, IL-6, IL-10, and hepatocyte growth factor (HGF); all are shown to be immunomodulatory. … These exosomes can also consist of VEGF and matrix metalloproteinase-9 (MMP-9) which aid in angiogenesis and tissue repair.
Somatrogon
go.drugbank.com/drugs/DB14960ApprovedInvestigationalGrowth hormone is a peptide hormone secreted by the pituitary gland that plays a crucial role in promoting longitudinal growth during childhood and adolescence and regulating metabolic function in adulthood … [A241485] Somatrogon was produced in Chinese Hamster Ovary (CHO) cells using recombinant DNA technology.
Sutilain
go.drugbank.com/drugs/DB09379ApprovedWithdrawn[T169] Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.[L2368] … Sutilain is a member of the keratase family which includes agents such as papain. It is able to dissolve the intercellular matrix which helps with desquamation.
Practolol
go.drugbank.com/drugs/DB01297ApprovedA beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias.
Synonyms: N-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)acetamideTildrakizumab
go.drugbank.com/drugs/DB14004ApprovedInvestigationalTildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis [A32255]. … A study was performed on the pharmacokinetics of this drug on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects [A32257].
Brivaracetam
go.drugbank.com/drugs/DB05541ApprovedInvestigationalBrivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184]. … It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 [L760].
Somapacitan
go.drugbank.com/drugs/DB15093ApprovedInvestigational[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. … Somapacitan, also known as NNC0195-0092,[A219136] is a growth hormone analog indicated to treat adults with growth hormone deficiency.